Furthermore, many different observations have suggested that NLRP3 is also involved in NASH-liver fibrosis evolution: the deletion of the NLRP3 gene or the pharmacological blockade of NLRP3 inflammasome reduced liver fibrosis in animal models of NAFLD/NASH [51,52]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.